Work in the Conrad laboratory was supported by Deutsche Forschungsgemeinschaft (DFG) (CO 291/7-1, 428858739 and the Priority Program SPP 2306 (CO 291/9-1, 461385412
doi:10.1016/j.fertnstert.2023.10.017 Andersen, J
You can read the abstract of this article at LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial PubMed (nih.gov)
Because the nasal mucosa (the lining inside the nose) is highly vascular, it can allow fairly steady absorption of certain peptides into circulation without the need for an injection
So there's a lot of, you know, Davis and Claire, I know he can be controversial too, like Michael Greger and these other guys, but he's got some interesting data on the benefits of changing sort of macro ratios for a longevity
While some of the trials reported a decrease in appetite as a side effect, like the ADJUNCT trials (60), it should be noted that this is one of the main mechanisms of action of these drugs to achieve weight loss